DRAXIS Radiopharmaceuticals Division Applies To FDA To Market Cardiac Imaging Product
Sun, 04 Feb 2007 08:00 AM EST
... DRAXIMAGE, the radiopharmaceutical division of DRAXIS Health Inc. (TSX: DAX) (Nasdaq: DRAX), has submitted an Abbreviated New Drug Application (ANDA) to the U.S. [click link for full article] ...
Related Topics
- Magnetic Resonance Imaging
- Cardiac Rehabilitation
- Consumer Product Safety
- Research
- Cardiac Risk
- Household Poisons
- Mammography
- Diagnostic Imaging
- Fire Safety
- Developmental Disabilities & Disorders
- Developmental Disabilities
- Cerivastatin - Withdrawn From The Market
- Magnetic Resonance Imaging/mri
- Rofecoxib
- Tragacanth
- Tacrolimus ointment
- Nuclear Imaging
- Rofecoxib Oral Suspension
- Imaging of the Urinary Tract
- Magnetic Resonance Imaging Test

Not Signed In -


